Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts. Pediatr Dermatol 2023;40(6):1057-1059
Date
08/19/2023Pubmed ID
37596908DOI
10.1111/pde.15415Scopus ID
2-s2.0-85168570424 (requires institutional sign-in at Scopus site)Abstract
Numerous studies have investigated the efficacy of intralesional immunotherapy for warts, but there are a lack of studies investigating the efficacy of alternative intralesional immunotherapies following failure of initial intralesional immunotherapy. In this retrospective study, we aimed to investigate the efficacy of intralesional measles, mumps, and rubella vaccine for the treatment of pediatric warts following failure of intralesional therapy with Candida antigen. Following intralesional measles, mumps, and rubella vaccine administration, 8/51 (15.5%) patients had complete resolution of their warts, 6/51 (12%) had near complete resolution, 19/51 (37%) had partial improvement, 12/51 (23.5%) had no change, and 6/51 (12%) had worsening. Although limited by retrospective nature and low sample size, our results demonstrate that intralesional immunotherapy with measles, mumps, and rubella vaccine provides an alternative therapeutic option for the treatment of recalcitrant pediatric warts in patients who fail to respond to intralesional Candida antigen.
Author List
Ulschmid CM, Patel J, Pan AY, Liegl M, Holland KEAuthors
Kristen E. Holland MD Associate Professor in the Dermatology department at Medical College of WisconsinAmy Y. Pan PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antigens, FungalCandida
Child
Humans
Immunotherapy
Injections, Intralesional
Measles
Measles-Mumps-Rubella Vaccine
Mumps
Retrospective Studies
Rubella Vaccine
Treatment Outcome
Warts
